Merck announces results of phase III trial of Recarbrio (imipenem, cilastatin, and relebactam) versus piperacillin and tazobactam (PIP/TAZ) in adult patients with hospital-acquired or ventilator-associated bacterial pneumonia

Recarbrio met its primary and key secondary endpoints, demonstrating non-inferiority compared to PIP/TAZ. For patients treated with Recarbrio, day 28 all-cause mortality (primary endpoint) was 15.9% (42/264) compared with 21.3% (57/267) in PIP/TAZ group.

SPS commentary:

The FDA accepted for review a supplemental New Drug Application for Recarbrio in hospital-acquired or ventilator-associated bacterial pneumonia in February 2020.

Biospace Inc.